Which role for brexpiprazole, a new dopamine D2 partial agonist, in the treatment of schizophrenia?
作者信息
Citrome Leslie
出版信息
Evid Based Ment Health. 2016 May;19(2):e6. doi: 10.1136/eb-2015-102143. Epub 2016 Apr 5.
Abstract
摘要
相似文献
1
Which role for brexpiprazole, a new dopamine D2 partial agonist, in the treatment of schizophrenia?新型多巴胺D2部分激动剂布雷哌唑在精神分裂症治疗中扮演何种角色？
Evid Based Ment Health. 2016 May;19(2):e6. doi: 10.1136/eb-2015-102143. Epub 2016 Apr 5.
2
Brexpiprazole for the treatment of schizophrenia.用于治疗精神分裂症的布雷哌唑
Expert Rev Neurother. 2016;16(2):109-22. doi: 10.1586/14737175.2016.1129901. Epub 2016 Jan 20.
3
Dopamine partial agonists: a new class of antipsychotic.多巴胺部分激动剂：一类新型抗精神病药物。
CNS Drugs. 2004;18(4):251-67. doi: 10.2165/00023210-200418040-00005.
4
Dopamine D2 receptor partial agonists in the treatment of schizophrenia -example of brexpiprazole.多巴胺 D2 受体部分激动剂在精神分裂症治疗中的应用——以布瑞哌唑为例。
Psychiatr Pol. 2024 Aug 31;58(4):581-593. doi: 10.12740/PP/174593.
5
Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?用于精神分裂症及作为重度抑郁症辅助治疗的布雷哌唑：对这种新获批抗精神病药物的疗效和安全性概况的系统评价——治疗所需人数、伤害所需人数以及受益或受害可能性是多少？
Int J Clin Pract. 2015 Sep;69(9):978-97. doi: 10.1111/ijcp.12714. Epub 2015 Aug 6.
6
Switching antipsychotics to partial dopamine D2-agonists in individuals affected by schizophrenia: a narrative review.将抗精神病药物转换为部分多巴胺 D2 激动剂治疗精神分裂症患者：叙述性综述。
Int J Psychiatry Clin Pract. 2023 Nov;27(4):367-384. doi: 10.1080/13651501.2023.2231047. Epub 2023 Jul 10.
7
Brexpiprazole: A Partial Dopamine Agonist for the Treatment of Schizophrenia.布雷哌唑：一种用于治疗精神分裂症的部分多巴胺激动剂。
Rev Recent Clin Trials. 2018 Jan 31;13(1):37-44. doi: 10.2174/1574887112666170821114831.
8
Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial.初治及非初治精神分裂症患者中多巴胺D2受体拮抗剂和部分激动剂的随机对照试验
Eur Arch Psychiatry Clin Neurosci. 2015 Oct;265(7):579-88. doi: 10.1007/s00406-015-0605-1. Epub 2015 May 28.
9
Brexpiprazole: a new dopamine D₂receptor partial agonist for the treatment of schizophrenia and major depressive disorder.布雷哌唑：一种用于治疗精神分裂症和重度抑郁症的新型多巴胺D₂受体部分激动剂。
Drugs Today (Barc). 2015 Jul;51(7):397-414. doi: 10.1358/dot.2015.51.7.2358605.
10
Brexpiprazole: a new leaf on the partial dopamine agonist branch.布雷哌唑：部分多巴胺激动剂领域的新进展。
Australas Psychiatry. 2018 Feb;26(1):92-94. doi: 10.1177/1039856217732473. Epub 2017 Oct 10.
引用本文的文献
1
Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity.阿立哌唑，一种具有部分激动作用和功能选择性的药物。
Curr Neuropharmacol. 2017 Nov 14;15(8):1192-1207. doi: 10.2174/1570159X15666170413115754.
本文引用的文献
1
The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out.多巴胺受体部分激动剂的基础要点——阿立哌唑、布雷哌唑和卡立哌唑：区分这些药物的15分钟挑战
Int J Clin Pract. 2015 Nov;69(11):1211-20. doi: 10.1111/ijcp.12752. Epub 2015 Oct 18.
2
The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?布雷哌唑的临床前概况：其对精神疾病治疗的临床相关性是什么？
Expert Rev Neurother. 2015 Oct;15(10):1219-29. doi: 10.1586/14737175.2015.1086269. Epub 2015 Sep 24.
3
Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?用于精神分裂症及作为重度抑郁症辅助治疗的布雷哌唑：对这种新获批抗精神病药物的疗效和安全性概况的系统评价——治疗所需人数、伤害所需人数以及受益或受害可能性是多少？
Int J Clin Pract. 2015 Sep;69(9):978-97. doi: 10.1111/ijcp.12714. Epub 2015 Aug 6.
4
A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia.一项关于固定剂量布瑞哌唑治疗成人急性精神分裂症的多中心、随机、双盲、对照3期试验。
Schizophr Res. 2015 May;164(1-3):127-35. doi: 10.1016/j.schres.2015.01.038. Epub 2015 Feb 12.
Zotero 插件